---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-050007"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T06:45:02.863286+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# F351 Phase III enrollment completed ahead of schedule for HBV liver fibrosis

## Summary
- Beijing Continent completed subject enrollment for F351 Phase III trial in China, more than two months ahead of initial expectation.
- Trial aims to confirm efficacy of F351 for liver fibrosis associated with chronic hepatitis B; safety comparable to Phase II.
- F351 received Breakthrough Therapy designation from NMPA in 2021; top-line data expected after 52-week data collection.
- BC, the trial sponsor, will become a subsidiary of Catalyst Biosciences per prior October 24 disclosure; no change to GNI consolidation.

## SEC filing metadata
- accession: 0001140361-23-050007
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123050007/0001140361-23-050007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123050007/ny20009756x7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-050007
- JSON: https://secwatch.observer/filing/0001140361-23-050007.json
- Plain text: https://secwatch.observer/filing/0001140361-23-050007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.